New drug timing strategy aims to shield patients from dangerous transplant complication
NCT ID NCT06315309
Summary
This study is testing whether changing when a key drug is given can better prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. It will enroll about 29 adults with leukemia or related disorders who are receiving a transplant from a donor. The main goal is to see if a new schedule for the drug ATG, combined with standard medications, helps patients survive for one year without severe GVHD, cancer relapse, or needing strong immune-suppressing drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.